Amsterdam-based SERDA Therapeutics, a three way partnership firm between Smith & Nephew Worldwide and NLC, introduced that it has accomplished a €2M funding spherical, led by NLC Well being Affect Fund.
The funding will propel the event of SERDA’s enzymatic wound debridement product, SN514.
With a profitable Investigational New Drug (IND) submission, the corporate is gearing in direction of commercialisation with a Section 1 scientific trial underway, adopted by a Section IIa research on burn wounds later this yr.
Supported by the US Military’s medical analysis division, this marks an “essential step” in making SERDA’s wound care options accessible to these in want.
What does SERDA Therapeutics supply?
Based in 2020, SERDA Therapeutics is growing a proprietary product for wound debridement tailor-made to deal with extreme burn accidents and power ulcers, similar to stress ulcers, open leg wounds, and diabetic foot ulcers.
Gabor Heltovics, CEO of SERDA, says, “Our mission at SERDA is to revolutionise wound debridement and enhance the lives of these affected by such circumstances.”
“Our enzymatic debridement know-how is being developed to mix distinctive long-term stability with quick removing of broken tissue, considerably lowering therapeutic time and discomfort. This strategy wouldn’t solely pace up restoration but in addition enhance the standard of life for sufferers coping with power circumstances and burn accidents.”
Hundreds of thousands worldwide endure power and burn wounds, worsened by ageing and diabetes. Conventional strategies like surgical procedure and enzymatic debridement are expensive, painful, and sometimes ineffective.
“SERDA’s modern strategy to wound care has the potential to considerably cut back each the healthcare burden of power wounds and the non-public affect on sufferers,” says, Jaap Haemers, Funding Supervisor at NLC.
“We’re excited to assist SERDA as they transfer nearer to bringing this very important know-how to market,” provides Haemers.
Temporary concerning the NLC HealthImpact Fund
The NLC Well being Affect Fund, NLC’s newest and largest fund so far, is devoted to investing in early-stage healthcare improvements. It goals to assist ventures at completely different maturity ranges by offering preliminary and follow-on funding.
The fund gives buyers entry to a various portfolio of impactful healthtech ventures, capturing excessive return potential within the early stage. At the moment, NLC is elevating funds for the second shut of the Well being Affect fund.
